作者
Benjamin Farahnik, Kourosh Beroukhim, Tian Hao Zhu, Michael Abrouk, Mio Nakamura, Rasnik Singh, Kristina Lee, Tina Bhutani, John Koo
发表日期
2016/3
来源
Dermatology and therapy
卷号
6
页码范围
25-37
出版商
Springer Healthcare
简介
Introduction
Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising.
Methods
We conducted an extensive literature search using the PubMed database to assess the efficacy and safety profile of ixekizumab. The search included the following key words: “psoriasis” and “IL-17” or “ixekizumab.” We also reviewed citations within articles to identify relevant sources.
Results
By week 12, the percentage of patients achieving a 75% improvement from baseline Psoriasis Area and Severity Index (PASI 75) was comparable among the three Phase III trials (UNCOVER-1, 89%; UNCOVER-2, 90%; UNCOVER-3, 87 …
学术搜索中的文章
B Farahnik, K Beroukhim, TH Zhu, M Abrouk… - Dermatology and therapy, 2016